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ARTICLE
Cowden Syndrome–Affected Patients with PTEN Promoter
Mutations Demonstrate Abnormal Protein Translation
Rosemary E. Teresi, Kevin M. Zbuk, Marcus G. Pezzolesi, Kristin A. Waite, and Charis Eng
Germline mutations of PTEN (phosphatase and tensin homolog deleted on chromosome 10) are associated with the
multihamartomatous disorder Cowden syndrome (CS). Moreover, patients with CS with germline PTEN promoter mu-
tations have aberrant PTEN protein expression and an increased frequency of breast cancer. Here, we examined the
downstream effect of five PTEN promoter variants (5861G/T, 5853C/G, 5834C/T, 5798G/C, and 5764G/A) that are
not within any known cis-acting regulatory elements. Clinically, all five of these patients have been given diagnoses of
breast, thyroid, and/or endometrial cancer. We demonstrated that protein binding to the PTEN promoter (5893 to5755)
was not altered in the five variants when compared with the wild-type (WT) promoter. However, reporter assays indicated
that three of the variants (5861G/T, 5853C/G, and 5764G/A) demonstrated an ∼50% decrease in luciferase activity
compared with the WT construct. PTEN messenger RNA (mRNA) levels were not altered in these variants, whereas
secondary structure predictions indicated that different PTEN 5′ untranslated region transcript-folding patterns exist in
three variants, suggesting an inhibition of protein translation. This was confirmed by PTEN protein analysis. These data
indicate that variants causing large mRNA secondary structure alterations result in an inhibition of protein translation
and a decrease in PTEN protein expression. These data emphasize the importance of PTEN promoter nucleotide variations
and their ability to lead to CS progression by a novel regulatory mechanism. Importantly, these patients have a high
prevalence of breast, thyroid, and endometrial malignancies; thus, understanding of the mechanism of PTEN dysfunction
in these patients will lead to more-sensitive molecular diagnostic and predictive testing and, ultimately, to rational
targeted therapies to treat or prevent malignancy.
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Germline mutations in PTEN (phosphatase and tensin ho-
molog deleted on chromosome 10), a tumor-suppressor
gene on 10q23, occur in 85% of patients with Cowden
syndrome (CS [MIM 158350]).1–5 This syndrome affects ∼1
in 200,000 individuals; however, this is generally thought
to be an underestimation.6 CS is characterized by hamar-
tomas of multiple organs and increased risks of neoplasia.
Patients given diagnoses of CS have a 25%–50% lifetime
risk of developing female breast cancer, whereas the risk
in the general population is ∼13%.7,8 Patients with CS
have an ∼10% lifetime risk of developing thyroid cancer,
which tends to be follicular, compared with a !1% risk in
the general population. Furthermore, there is an ∼5%–
10% lifetime risk of endometrial cancer for patients with
CS, compared with ∼2%–4% in the general population.3,
7 Proper recognition and diagnosis of CS is crucial not only
because of the increased risk of cancers observed in this
syndrome but also because of the morbidity, and even
mortality, associated with its nonmalignant features.
Germline PTEN mutations are also found in 65% of
patients with Bannayan-Riley-Ravalcaba syndrome (BRRS
[MIM 153480]), characterized by macrocephaly, lipoma-
tosis, hemangiomatosis, and speckled penis.3,9 In addition
to BRRS, a number of other syndromes, including Proteus
syndrome (MIM 176920), Proteus-like syndrome,6 and
autism,10 share germline PTEN mutations as an etiology
and have been classified as PTEN hamartoma tumor syn-
dromes (PHTS). It is recommended that they all be man-
aged in a similar manner to CS if a pathogenic PTEN mu-
tation is identified.2
Before 2003, PTEN mutations had been identified in
80% of patients meeting strict diagnostic criteria for CS.8,11
CS is believed to be monogenic; therefore, determining
the cause of PTEN dysfunction in the remaining 20% of
patients is vitally important to the practice of personalized
genetic health care. Our laboratory began aggressively pur-
suing alternative mechanisms of PTEN inactivation, in-
cluding interrogating the mutation status of its own pro-
moter. We have identified mutations in the PTEN pro-
moter in patients with CS and have shown that ∼10% of
previously classified PTEN mutation–negative patients
have nucleotide variants within the full-length promoter.3
Furthermore, these mutations resulted in both a decrease
in PTEN protein expression and loss of function.3 Inter-
estingly, in this initial study, eight (89%) of nine patients
with germline PTEN promoter mutations had breast can-
cer, although the overall number of organs involved was
generally low in these patients, suggesting that these mu-
tations may preferentially confer very high penetrance for
breast cancer.3
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Previous investigations of the PTEN promoter, including
our own, have focused on areas within known transcrip-
tion-factor binding sites. However, we have now identified
variants of unknown significance (VUSs) 3′ of any known
cis-acting elements. On the basis of our previous work,12–
14 we predict that these VUSs might be pathogenic. Given
the dilemma faced by the clinical cancer geneticist and
genetics counselor when counseling patients with VUSs,
an understanding of the molecular consequences of these
promoter VUSs has important implications for patient
care. In this study, we investigated both transcriptional
and translational downstream effects of PTEN promoter
VUSs in patients with CS. Our data demonstrate that cer-
tain PTEN promoter VUSs in patients with CS result in
decreased PTEN expression through dysfunctional trans-
lation, rather than through altered transcription.
Material and Methods
Patient Recruitment
Human subjects were recruited from multiple institutions
throughout the United States. All samples were acquired with
informed consent in accordance with protocol approved by the
human subjects protection committees of their respective insti-
tutions. Patients with CS used in this study were classified in
accordance with both the National Comprehensive Cancer Net-
work and the International Cowden Consortium operational di-
agnostic criteria, and 186 healthy individuals served as controls.
In our entire series, patients are ∼85% white, ∼5% black, and 10%
other (including Hispanic, Asian, etc.). For this particular study,
both cases and controls were whites of western and northern
European origin.
DNA Isolation and Promoter-Mutation Analysis
Unaffected control and patient genomic DNA was isolated by
the Genomic Medicine Biorepository of the Cleveland Clinic
Genomic Medicine Institute. Primers were designed to amplify
the full PTEN promoter between –1389 and –715 (forward 5′-
GCGTGGTCACCTGGTCCTTT-3′, reverse 5′-GCTGCTCACAGGC-
GCTGA-3′), and DNA was PCR amplified in 20-ml reactions with
the use of HotStar and Q Solution (Qiagen). The PCR conditions
consisted of 30 cycles at the annealing temperature of 55C. PCR
products were treated with exonuclease I (New England Biolabs)
and shrimp alkaline phosphatase (USB) and were analyzed on
both strands by direct sequencing (ABI 3730xl DNA Analyzer
[Genomics Core Facility, Lerner Research Institute]). Variants
were detected by direct analysis compared with unaffected con-
trol sequence through Lasergene software (DNASTAR).
Cell Culture
The MCF-7 breast cancer and HeLa cell lines were maintained
at 37C with 5% CO2 in Dulbecco’s modified Eagle medium
containing 10% fetal bovine serum (FBS) and 100 units/ml each
of penicillin and streptomycin. Clonal lymphoblastoid cell lines
(LBCLs) were generated by the Genomic Medicine Biorepository
from patients with CS and unaffected, healthy controls. LBCLs
were cultured in RPMI medium supplemented with 20% FBS and
100 units/ml of penicillin and streptomycin.
Protein Isolation
Total protein from LBCLs was harvested using M-PER (Pierce) lysis
buffer containing phenylmethanesulphonylfluoride (0.75 mg/
ml), benzamidine hydrochloride (0.5 mg/ml), leupeptin (2 mg/
ml), aprotinin (2 mg/ml), pepstatin (2 mg/ml), b-glycerophosphate
(10 mM), NaOV (0.2 mM), and NaF (25 mM). Cells were incubated
at room temperature with lysis buffer for 1 min before harvesting.
Samples were centrifuged at 16,000 g for 10 min at 4C, to remove
cellular debris. The resulting supernatant was stored at 80C.
Nuclear protein was extracted according to Pierce’s isolation pro-
tocol. In brief, cells were collected by scraping with PBS and were
washed several times. Cell pellets were incubated with the ap-
propriate amount of Cer I buffer on ice to isolate the cytoplasmic
fraction. The remaining extract was incubated with the appro-
priate amount of Ner I buffer on ice with several agitation steps
to isolate the nuclear fraction. The resultant cytoplasmic and nu-
clear extracts were stored at 80C. Protein concentration was
determined using the bicotinic method, with the use of BSA as
a standard.15
Electromobility Shift Assay
For study of the VUSs in a heterozygous state, the PTEN promo-
ter sequence (893 to 755) was isolated through PCR amplifi-
cation from either normal genomic DNA or from genomic DNA
obtained from a patient with CS who has an identified variant.
The DNA was PCR amplified for 30 cycles at the annealing tem-
perature of 55C in 20-ml reactions, with the use of HotStar and
Q Solution (Qiagen) (forward 5′-ATGCGCTGCGGCAGGATAC-3′,
reverse 5′-CTCATCTCCCTCGCCTGA-3′). To study the VUSs in a
homozygous state, the above PCR products were cloned into
TOPO-TA vectors, and product sequences were verified by direct
DNA sequencing (ABI 3730xl DNA Analyzer). Nested PCR was
subsequently performed with the above primers, for isolation of
only the PTEN VUSs. Each of the above products was radiolabeled
with 32P-gATP via T4 kinase. For examination of DNA-protein
interaction, 1 ng of radiolabeled probe was incubated with 2 mg
of nuclear protein extract for 20 min at room temperature with
binding buffer containing 10 mM HEPES (pH 7.5), 2.5 mM MgCl2,
50 mM NaCl, 0.5 mM dithiothreitol, 4% glycerol, 1 mg/ml BSA,
and 2 mg poly dI/dC. Unlabeled probe in 5# molar excess was
used as the specific competitor, whereas a random oligonucleo-
tide sequence was used as the nonspecific competitor. DNA-pro-
tein complexes were resolved on a 4% nondenaturing PAGE gel
at 150 V for 3.5 h at 4C and were visualized using a Phospho-
Imager (Amersham Biosciences).
Reporter Assay
PTEN (893 to 1) was PCR amplified from control genomic
DNA or from genomic DNA from patients with CS (forward 5′-
GCGTGGTCACCTGGTCCTTT-3′, reverse 5′-GCTGCTCACAGGC-
GCTGA-3′) and was subsequently cloned into a TOPO-TA vector.
DNA was PCR amplified using 55C as the annealing temperature
for 30 cycles. All PCR-amplification products were verified by di-
rect DNA sequencing (ABI 3730xl DNA Analyzer), and positive
clones were subcloned into a pGL3.1-Basic vector (Promega). In
the event that positive variant clones were not obtained, site-
directed mutagenesis was performed, as described by the man-
ufacturer’s protocol (GeneTailor Site-Directed Mutagenesis Sys-
tem [Invitrogen]). Site-directed mutagenesis was performed on
the wild-type (WT) PTEN promoter in a TOPO-TA vector.
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Figure 1. Schematic diagram of the PTEN promoter. PTEN’s full-length promoter lies between 1344 and 745 (white bar), and the
minimal promoter lies between 958 and 821 (gray bar). Within this region, the five nucleotide variants (black triangles) 861G/T,
853C/G, 834C/T, 798G/C, and 764G/A have been identified in a subset of patients with classic CS. The nearest 5′ transcription
factors are EGR1 (dotted bar) and Sp1 (black bar).
To determine promoter activity, 6-well plates of MCF-7 or HeLa
cells were cotransfected with 1 mg/well of a PGL3_PTEN construct,
and 50 ng/well Renilla luciferase control plasmid with 3 ml/well
of FuGene (Roche), as described by the manufacturer. After 48 h,
cells were harvested with 1# passive luciferase lysis buffer (Dual-
Luciferase Reporter Assay System [Promega]) and were analyzed
on a luminometer (LMax 11384 [Molecular Devices]) with the use
of Renilla luciferase as an internal transfection control.
Western Blot
Fifteen micrograms of protein was prepared by the Laemelli
method,16 was separated on 10% SDS-PAGE gel, and was electro-
phoretically transferred onto nitrocellulose. Equal protein load-
ing between conditions was confirmed by staining with Ponceau
S solution. Nonspecific binding was blocked by incubation of the
nitrocellulose blots with 5% milk in Tris-buffered saline–Tween
(TBS-T) (100 mM Tris [pH 7.5], 1 M NaCL, and 1% Tween-20) for
1 h at room temperature. Blots were then incubated with the
primary antibody, either anti-PTEN (Cascade Bioscience) or anti-
actin (Sigma), at a dilution of 1:1,000 in 3% BSA for 2 h at room
temperature. After the primary incubation, the blots were washed
with TBS-T for 1 h, with frequent changes of buffer. Blots were
then incubated with the appropriate secondary antibody con-
jugated with horseradish peroxidase (Promega) at a dilution of 1:
2,500 in 5% milk overnight at 4C and were washed with TBS-T
for 1 h. Protein bands were visualized using enhanced chemi-
luminescence, as described by the manufacturer (Amersham
Pharmacia).
RT-PCR and Real-Time PCR
HeLa and MCF-7 cells, transfected with the above-described
PGL3_PTEN –893 to –1 construct, and LBCLs were collected and
were subsequently washed three times with PBS, through cen-
trifugation. Total RNA was extracted from cells, in accordance
with the Gentra Versagene RNA Purification System Protocol, and
was then converted to cDNA by Superscript II Reverse Transcrip-
tase after DNase treatment. The resultant cDNA was subjected to
multiplex PCR amplification with the use of primers specific to
luciferase (forward 5′-TCAAAGAGGCGAACTGTGTG-3′, reverse 5′-
GGTGTTGGAGCAAGATGGAT-3′), PTEN exons 3 and 5 (forward
5′-TGGATTCAAAGCATAAAAACCA-3′, reverse 5′-AAAAGGATAT-
TGTGCAACTCTGC-3′), and b-actin (Quantum RNA b-actin [Am-
bion]). Primers were allowed to anneal at 55C for 28 cycles. The
products from the PCRs were run on a 1% agarose gel containing
ethidum bromide and were visualized under a UV light.
Real-time PCR was performed using the ABI 7500 real-time PCR
system (ABI/Perkin Elmer) with the use of a SYBR Green–based
assay, as described elsewhere.17 Primers were designed to amplify
cDNA incorporating a portion of the PTEN transcript encoded by
exons 7 and 8 (forward 5′-CCACAAACAGAACAAGATG-3′, reverse
5′-CTGGTCCTGGTATGAAGAAT-3′). Primers amplifying a por-
tion of GAPDH were used as the control (forward 5′-CCATCTT-
CCAGGAGCGAGA-3′, reverse 5′-AAATGAGCCCCAGCCTTCT-3′).
The thermal cycling conditions were 50C for 2 min and 95C
for 10 min, followed by 40 cycles of denaturing at 95C for 15 s
and annealing and extension at 60C for 1 min. All the reactions
were performed in triplicate, and the comparative CT method was
used for the quantification of the expression for each segment,
by use of GAPDH as a normalization control. Each PCR generated
only the expected amplicon, as shown by the melting tempera-
ture profiles of the final products and by gel electrophoresis.
Statistical Analysis
Statistical analysis was done using Student’s t test. Data are means
SDs of three independent experiments and are normalized to
a control. is considered statistically significant.P ! .05
Results
PTEN Promoter VUSs Demonstrate Similar
Transcription-Factor Binding
Despite the clear significance of PTEN dysfunction in the
development of many types of cancers, the mechanisms
Figure 2. EMSA analysis probed with radiolabeled PTEN promoter from 893 to 755, either WT or variant. A, Each promoter probe,
incubated in either the presence (Bd) or absence (Ng) of nuclear protein. The WT PTEN promoter (lanes 1 and 2), 861G/T (lanes 3
and 4), 853C/G (lanes 5 and 6), 834C/T (lanes 7 and 8), 798G/C (lanes 9 and 10), and 764G/A (lanes 11 and 12) demonstrate
nuclear-protein binding. A representative blot from three individual experiments is displayed. B, Quantification of nuclear-protein
binding to the PTEN promoter, confirming insignificant differences between WT (lane 1) and the five variants (lanes 2–6; ).P 1 .050
EMSA results are depicted as fold change compared with WT PTEN promoter and are shown in graphical format (Student’s t test). C,
Radiolabeled WT PTEN promoter from 893 to 755. Nuclear protein either was not incubated with the probe (Ng) or was incubated
with the probe (Bd) to test binding. Competition assays were performed with a nonspecific competitor (Nn), unlabeled WT promoter
probe (Sp), and cold PTEN promoter variant probes (lanes 5–9). A representative blot from three individual experiments is displayed.
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Table 1. Increased Cancer Frequency in Patients with CS with PTEN Promoter Variants
Mutation
Malignant Breast
Cancer
Benign Breast
Neoplasm
Follicular Thyroid
Cancer
Endometrial
Cancer
861G/T No Yes Yes Yes
853C/G Yes No Yes No
834C/T Yes No No No
798G/C No Yes Yes Yes
764G/A No Yes No Yes
that regulate PTEN’s promoter and 5′ UTR remain largely
unknown. Figure 1 illustrates that the generally recog-
nized full-length PTEN promoter is localized to positions
1344 to 745, and the minimal promoter to 958 to
821, with 1 representing the ATG site.18 While scan-
ning the full-length PTEN promoter for nucleotide vari-
ants, we identified five VUSs (861G/T,853C/G,834C/
T,798G/C, and764G/A) in five unrelated patients with
a clinical diagnosis of CS, which were absent in 186 un-
affected, healthy controls. All five patients with CS had
benign or malignant breast disease, and, importantly,
three (60%) of the five had two component malignancies
associated with CS (table 1). Additionally, all five of the
VUSs used in this study are located 3′ of any known PTEN
transcription-factor binding site (fig. 1). Previous data
from our laboratory indicate that mutations within reg-
ulatory elements or transcription-factor binding sites in-
terfere with normal transcriptional activity.12–14 However,
these five VUSs are not predicted to alter any known cis-
acting regulatory elements; therefore, the functional sig-
nificance of these variants is even more difficult to
ascertain.
To determine what role these five VUSs may play in
PTEN regulation, we performed electromobility shift as-
says (EMSAs) to find out if nuclear protein has the ability
to associate with the promoter at this region. Interestingly,
we found that nuclear protein does bind to the WT PTEN
promoter from 893 to 755, suggesting that there is a
yet-to-be-identified transcription-factor binding site in
this region. We continued further to determine whether
the nucleotide variants resulted in altered DNA-protein
complex formation when compared with the WT PTEN
promoter. EMSAs for each VUS were performed in either
a homozygous state, where only the variant allele was
present, or in a heterozygous state, where both the WT
and variant allele were present. This allowed us to deter-
mine whether the variant allele has the ability to inhibit
the WT allele’s function. As expected, no DNA-protein
complex was observed when nuclear protein was not
added to the reaction mixture (fig. 2A, Ng, lane 1), and
nuclear protein does bind to the WT PTEN promoter from
–893 to –755 (fig. 2A, Bd, lane 2). Unexpectedly, we ob-
served that nuclear protein was also able to bind to the
PTEN promoter VUSs in both a homozygous and a het-
erozygous state (fig. 2A, Bd, lanes 4, 6, 8, 10, and 12).
Furthermore, these interactions did not differ significantly
between the WT and VUS PTEN promoter probes (fig. 2B).
In addition, the WT PTEN promoter DNA-protein complex
could be competed with a cold unlabeled VUS probe (fig.
2C). Taken together, these data suggest that the DNA-pro-
tein interaction at this site is not affected by these specific
promoter VUSs.
PTEN Promoter–Reporter Assays Demonstrate That VUSs
Significantly Inhibit Luciferase Activity
The above data suggest that transcription-factor binding
at positions 893 to 755 is not altered in patients who
harbor VUSs within this region and that formation of
this complex may not directly contribute to disease path-
ogenesis. To gain more insight into the potential mech-
anism(s) of PTEN dysfunction manifested by these vari-
ants, we examined the ability of each VUS to promote
PTEN transcription, via reporter assays. We observed that
the WT PTEN (positions 893 to 1) had a basal level of
luciferase activity (fig. 3, WT). Two of the patient promoter
VUSs,834C/T and798G/C, had similar luciferase read-
outs (fig. 3). In contrast, three of the VUSs showed an
inhibition in luciferase activity when compared with the
WT PTEN construct. We found that the 861G/T and
764G/A VUSs had the greatest inhibition of luciferase
activity, ∼50% less than that of the WT construct (fig. 3)
( ). Additionally, the 853C/G VUS resulted in aP ! .001
40% decrease in luciferase activity, compared with WT
PTEN (fig. 3) ( ).P ! .001
Promoter VUSs Do Not Inhibit PTEN Transcription
The above experiment indicates that WT PTEN induces
more luciferase activity than do three of the patient-de-
rived promoter VUSs—specifically, the 861G/T, 764G/
A, and 853C/G variants. However, this experiment does
not indicate whether this effect is due to a decrease in
transcription or to an inhibition of protein translation.
To differentiate the two scenarios, we analyzed lucifer-
ase mRNA levels in the reporter-assay samples described
above. If the promoter VUSs are affecting transcription,
we would expect to see changes in luciferase mRNA lev-
els in those VUSs that caused significant decreases in lu-
ciferase activity. Unexpectedly, we found that luciferase
mRNA was equally expressed in the cells transfected with
the WT PTEN construct compared with cells transfected
with the patient-derived VUS promoters (fig. 4A), sug-
gesting that transcription efficiency and mRNA stability
are not compromised in these five VUSs.
We next examined the VUSs ex vivo by assessing
PTEN mRNA levels, using total RNA isolated from LBCLs
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Figure 3. Luciferase activity of PTEN 5′ UTR altered in three VUSs. MCF-7 cells were transfected with PGL3_PTEN 5′ UTR from 893
to 1, either WT or variant, as described in the “Material and Methods” section. After 48 h of treatment, cells were harvested, and
luciferase activity was measured. Each bar represents a mean SEM of three individual experiments. An asterisk (*) indicates P !
(Student’s t test)..001
from patients with promoter VUSs. We were able to as-
sess mRNA levels in three cell lines derived from the
patients with the following VUSs: 861G/T, 853C/G,
and 798G/C. We were unable to obtain LBCLs from the
patients with the remaining two VUSs (834C/T and
764G/A). By semiquantitative RT-PCR, we demonstrated
that there was equivalent PTEN mRNA expression in
LBCLs harboring promoter VUSs compared with those
obtained from unaffected, healthy controls (fig. 4B) (P 1
). To confirm these results, we performed a quantitative.05
real-time PCR assay. Similarly, no differences were ob-
served between PTEN mRNA levels in unaffected, healthy
controls compared with patient-derived promoter VUSs
(fig. 4C) ( ).P 1 .05
PTEN mRNA Secondary Structure Is Altered in VUSs versus
PTEN WT Promoter
As the above data suggest, these PTEN VUSs do not result
in altered transcription. Therefore, we next focused on
whether they result in abnormal translation, by studying
the PTEN mRNA transcript in more detail. Several labo-
ratories have previously suggested a number of putative
PTEN transcriptional start sites between 1031 and
9318–21; however, comparison of the human and mouse
PTEN cDNA sequences suggests that the transcript begins
around 925.20 In agreement with these results, we per-
formed PTEN RT-PCR from 869 to exon 9 and verified
that all five VUSs are included in the resulting transcript
(data not shown). Therefore, we hypothesized that the
inclusion of these nucleotide variants within the tran-
script causes an alteration of the normal mRNA secondary
structure and, consequently, an inhibiting protein trans-
lation. To determine if the mRNA secondary structure is
different in the VUSs compared with WT PTEN, we used
the MFOLD software program.22 We analyzed the PTEN 5′
UTR from positions 893 to 1, using both the WT se-
quence and sequences containing each of the VUSs. Sev-
eral potential secondary structures for each sequence were
predicted, with the most-stable structures illustrated in
figure 5.
The major secondary structure predicted for the WT
PTEN promoter is Y shaped with multiple loops (fig. 5,
WT). This shape is consistent with that predicted for the
834C/T and 798G/C VUSs (fig. 5). In contrast, the
861G/T, 853C/G, and 764G/A VUSs have different
predicted secondary structures compared with the WT
PTEN 5′ UTR. Whereas the 853C/G VUS maintains the
general Y shape, the loop structures are altered to create
a new branching arrangement (fig. 5,853C/G). Similarly,
the 764G/A VUS maintains a Y shape that is similar to
the WT 5′ UTR; however, it has lost almost all of its loops,
creating more of a sticklike structure (fig. 5, –764G/A).
Finally, the –861G/T VUS is structurally the most different
from WT PTEN (fig. 5, –861G/T). The general Y-shape ap-
pearance has been lost and has been replaced with a de-
tailed, intricate looping and branching configuration.
These structures suggest that PTEN translation may be al-
tered or inhibited in patients with these promoter VUSs,
particularly those that have the greatest deviation from
the WT structure, such as –861G/T.
Altered PTEN Protein Expression in Select VUSs
To determine whether these patients demonstrate altered
protein translation due to nucleotide variants within the
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Figure 4. WT and variant PTEN promoters demonstrating equal mRNA expression. A, HeLa or MCF-7 cells transfected with a PGL3_PTEN
893 to 1 construct, either WT or containing a VUS. Cells were harvested 48 h after transfection, and total RNA was extracted.
Luciferase (top panel) and actin (bottom panel) mRNA levels were measured by RT-PCR. (represents a mean SEM of threeP 1 .050
individual experiments). B, LBCLs from unaffected, healthy controls that were either PTEN WT (lanes 1–3) or patient derived with a
promoter VUS (861G/T [lane 4], 853C/G [lane 5], and 798G/C [lane 6]). LBCLs were harvested, and total RNA was extracted. PTEN
(bottom band) and actin (top band) mRNA levels were measured by RT-PCR. (represents a mean SEM of three individualP 1 .050
experiments). C, LBCLs from unaffected, healthy controls that were either PTEN WT (bars 1–3) or patient derived with a promoter VUS
(861G/T [bar 4], 853C/G [bar 5], and 798G/C [bar 6]). LBCLs were harvested, and total RNA was extracted. Real-time measured
PTEN and GAPDH mRNA levels are shown, with quantification of PTEN mRNA normalized to GAPDH levels. Real-time RT-PCR results are
depicted as DCt changes and are shown in graphical format. Each bar represents a mean SEM of three individual experiments. P 1
(Student’s t test)..050
promoter region, we examined PTEN protein expression
from the previously mentioned patient-derived LBCLs.
We found that protein isolated from unaffected, healthy
controls had similar PTEN protein expression (fig. 6A
and 6B, lanes 1–3). Comparable to our control samples,
normal PTEN protein expression was observed from pa-
tient-derived LBCLs with VUS –798G/C (fig. 6A and 6B,
lane 6). Protein lysate derived from patient LBCLs with
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Figure 5. MFOLD-predicted secondary structures resulting from the five VUSs in patients with CS. The most-stable mRNA secondary
structures predicted by MFOLD are illustrated here.
the 853C/G VUS had an ∼15% decrease in PTEN ex-
pression ( ) (fig. 6A and 6B, lane 5), whereas cellsPp .046
derived from VUS 861G/T had the largest decrease in
PTEN levels, at ∼40% of control protein ( ) (fig. 6AP ! .001
and 6B, lane 4). Interestingly, these protein results can be
seen as concurrent with the structural alterations observed
with the MFOLD software. The secondary structure of the
VUS 798G/C 5′ UTR does not predict a large change
compared with WT PTEN; therefore, one would predict
that PTEN protein levels would be comparable to WT
controls, as we observed here. In contrast, the secondary
structure predicted with the VUS 853C/G 5′ UTR pre-
dicted some alterations that correlate with the slight de-
crease in PTEN protein levels observed in this patient.
Finally, the VUS promoter with the greatest structural
change, 861G/T, demonstrated the largest alteration in
PTEN levels. Taken together, these data indicate that these
predicted alterations to the secondary structures of the 5′
UTR, including the PTEN promoter, which are consequent
to the VUSs in our patients with CS, inhibit normal trans-
lation of PTEN.
Discussion
Recently, the importance of gene regulation in the path-
ogenesis of hereditary cancer-predisposition syndromes
has been advanced though the interrogation of promoter
variation as a mechanism of disease development. PTEN
promoter variants and their consequences have been only
minimally studied; however, promoters within a few select
genes, such as the baculoviral IAP repeat-containing 5
gene (BIRC5, also known as survivin), have been examined
more extensively.23 Yet the majority of these studies have
looked specifically at known regulatory regions and/or
consensus sites within the promoter of interest. We hy-
pothesized that novel nontraditional regulatory mecha-
nisms within the PTEN promoter play an important role
in gene regulation. This indicates that variants within un-
known regulatory elements may be as significant as those
in known cis-acting regions. To test this hypothesis, we
studied five VUSs within the PTEN promoter that are not
within a known cis-acting element. The culmination of
our data reveals that protein translation is altered within
a subset of patients with CS who lack traditional exonic
or splice-site PTEN mutations but who harbor PTEN pro-
moter variants, particularly those resulting in large mRNA
structural changes compared with WT PTEN mRNA. These
data also demonstrate abnormal protein translation as a
novel mechanism of CS pathogenesis.
To date, analysis of PTEN’s promoter has identified
eight regulatory factors that have been implicated in
modulating PTEN’s transcription: early growth response-
1 (EGR1),24 nuclear factor–kappa B (NF-kB),21 Sp1,3,19 CBF-
1,25 p53,20 USF1,12 peroxisome proliferator-activated recep-
tor gamma (PPARg),26–28 and c-Jun15 (fig. 1). The five VUSs
(861G/T, 853C/G,834C/T,798G/C, and764G/A)
used in our studies reside in the full-length PTEN promo-
ter region between 893 and 755 but lie more 3′ of any
of these known transcription-factor binding motifs. Our
EMSA results, with use of PTEN 893 to 755 as bait,
demonstrated nuclear-protein binding (fig. 2), thus sug-
gesting that there may be a novel transcription-factor
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Figure 6. PTEN protein expression decreased in promoter variants
with the greatest mRNA secondary structure alterations. A, LBCLs
from unaffected, healthy controls that were either PTEN WT (lanes
1–3) or patient derived with a promoter VUS (861G/T [lane 4],
853C/G [lane 5], and 798G/C [lane 6]). LBCLs were harvested,
and total protein was extracted. PTEN (top panel) and actin (bottom
panel) protein levels were measured by western-blot analysis. B,
Quantification of PTEN protein normalized to actin levels. Western-
blot results are depicted as fold change and are shown in graphical
format: 861G/T ( ), 853C/G ( ), and 798G/P ! .001 Pp .046
C ( ). Each bar represents a meanSEM of three individualP 1 .050
experiments. An asterisk (*) indicates (Student’s t test).P ! .050
binding site contained within this region. Several poten-
tial transcription factors are anticipated to bind to this
region, but only two were predicted by multiple prediction
software programs: Sp1 (TESS29 and Alibaba30) and c-Myb
(TESS and TFSEARCH31). Sp1 is currently thought to be a
putative PTEN transcription factor because the full-length
PTEN promoter is very GC rich; however, research has yet
to concretely show that it binds to any particular region
of the promoter or has the ability to regulate its tran-
scription.3,18 c-Myb has been shown to be up-regulated
within tumors when PTEN expression is decreased,32 in-
dicating that it may be acting as a PTEN transcriptional
repressor; however, the pathway connecting the two has
yet to be determined. On the basis of these prediction
models, both Sp1 and c-Myb can be postulated as regu-
lators of PTEN expression; however, more in-depth studies
are necessary to determine the identity of this novel PTEN
transcription factor.
In our initial EMSA results, we expected to observe a
difference in this novel transcription factor’s ability to
bind to the PTEN promoter, since previous data from our
laboratory have shown that PTEN promoter alterations
within the p53 (1190 to 1157)13 and USF1 (2237 and
2058)12 binding sites inhibit both normal PTEN mRNA
expression and protein function. In contrast, data pre-
sented herein indicated that protein-binding inhibition is
not the primary mechanism of PTEN alterations (fig. 2).
Interestingly, our reporter-assay results indicated that sev-
eral of the VUSs had a decrease in luciferase activity (fig.
3), whereas, seemingly paradoxically, PTEN mRNA was
equally expressed relative to WT (fig. 4). This suggests that
normal protein translation is disrupted by these altera-
tions, whereas conventional mRNA transcription remains
unaffected. In 2001, Signori and colleagues observed a
similar effect caused by a variant located 3 nt upstream
of the ATG site, thus lying within the Kozak consensus
sequence of the 5′ UTR within BRCA1.33 This nucleotide
variant is thought to have weakened the Kozak sequence
enough to inhibit normal protein translation. In contrast
to Signori et al.,33 the variants discussed in this publication
did not immediately indicate this mechanism, and more
intricate analyses were necessary.
PTEN has a number of putative transcription start sites,
whose analysis reveals five potential Kozak translational
start sites. However, none of these start sites perfectly fit
the mammalian Kozak consensus sequence, GCCRCC-
ATGG, where the 3 and 4 positions are the most con-
served.34 Analyses of these ATG sites, 5′r3′, indicate that
they would produce 28-aa, 5-aa, 4-aa, 46-aa, and 403-aa
proteins. PTEN is just one of many genes that has the
potential to produce upstream ORFs and may not follow
the “first ATG” rule. Moreover, this tends to lead to leaky
scanning by the 40S ribosome, thus allowing for trans-
lation of one or several of the 5′ ORFs. In this situation,
the ribosomes do not fall off the transcript but do proceed
to scan 3′ to the true ATG site, thus allowing for the pro-
duction of the correct mRNA. This suggests that PTEN’s
long 5′ UTR with potential ORFs and a weak Kozak con-
sensus sequence make it more prone to influences from
nucleotide variants, which can subsequently decrease its
translation efficiency.35
Another mechanism that can confound normal pro-
tein-translation efficiency is through aberrant mRNA se-
condary structures. To determine whether modified PTEN
mRNA structure was the cause of altered protein transla-
tion in our patients, we used the MFOLD software program
to compare the WT PTEN promoter with the five VUSs.
Our results demonstrate that some of these VUSs contrib-
ute to the mRNA structure, thus creating a significantly
different configuration compared with WT PTEN (fig. 5).
This is important because normal mRNA primary and sec-
ondary structures are essential for the ability of mRNA-
binding proteins to both accurately bind and initiate and,
subsequently, to affect protein translation.35 Recently, Sax-
ena and colleagues identified an 11-bp deletion in MeCP2,
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103 nt upstream of the ATG site.36 Through the use of
mRNA structural prediction models, they concluded that
this deletion disrupted normal protein translation without
affecting MeCP2 transcription.
Studies of the nucleotide alterations isolated within
both BRCA1 and MeCP2, which specifically inhibit normal
translation and not gene transcription, are currently the
only known ones to demonstrate that promoter VUSs can
affect protein expression through such a mechanism.33,36
However, there have been a few recent examples of SNPs
within protein-coding regions that also alter the normal
protein outcome through translation. In both of these ex-
amples, it is hypothesized that synonymous SNPs induce
structural changes in mRNA structure, which ultimately
lead to the protein’s dysregulation. Kimchi-Sarfaty et al.37
report that specific MDR1 haplotypes, generated from si-
lent SNPs, inhibit normal protein translation and, sub-
sequently, its function. This is thought to occur through
the slowing of ribosomal scanning at these specific co-
dons.37,38 Furthermore, Nackley and colleagues39 described
three major haplotypes formed by four SNPs within the
human catechol-O-methyltransferase (COMT) gene, whose
MFOLD predictions indicated that the haplotypes result
in altered mRNA secondary structures. More interestingly,
a decrease in both protein expression and enzymatic ac-
tivity was produced from a haplotype containing two
synonymous SNPs.39 These data suggest that nucleotide
changes that may initially seem insignificant can disrupt
normal protein translation through alterations of mRNA
secondary structure.
As stated above, our reporter-assay, MFOLD-analysis,
and western-blot results are all in agreement with regard
to the 861C/G, 853C/G, and 789G/C VUSs. Because
of unavailability, we were unable to directly study the
834C/T and764G/A VUSs; however, one can speculate
on the likely outcome on the basis of the above results.
Our data indicate that the 834C/T VUS, which displays
no secondary structural differences compared with WT
PTEN mRNA, and which had only a slight decrease in
luciferase activity, would not have a decrease in PTEN pro-
tein expression. In contrast, one can hypothesize that the
764G/A variant would have a significant decrease in
PTEN protein expression. Similar to the 861C/G VUS,
the 764G/A VUS demonstrated a significant decrease in
luciferase activity and a large alteration in mRNA second-
ary structure, as predicted by MFOLD, when compared
with WT PTEN 5′ UTR.
It is thought that the decrease in translation efficiency
of these mRNA structures can be compensated for by
more-efficient translation through the regulation of the
eukaryotic translation initiation factor (eIF4F) complex.
This complex, which is composed of eIF4A, eIF4B, and
eIF4H, is involved in unwinding mRNA secondary struc-
tures to induce protein translation.40 These data suggest
that one could potentially modulate one or several of
these translation factors as a personal therapeutic target
for patients with PTEN promoter VUSs.
In 2003, our laboratory was the first to demonstrate the
pathogenicity of PTEN promoter variants in patients with
CS.3 These genetic alterations within PTEN’s promoter ap-
pear to correlate with a high prevalence of breast cancer
in this subset of patients. In agreement with these previous
data, the patients included in the current analysis all har-
bor promoter VUSs and exhibit a high prevalence of breast
neoplasia, as well as follicular thyroid and endometrial
cancer. All five patients with the PTEN promoter VUSs
interrogated in this study developed breast tumors (table
1). Two of these five patients were given diagnoses of
breast cancer, whereas the remaining three patients were
given diagnoses of benign breast neoplasms. In addition
to breast cancer, three of the five patients developed fol-
licular thyroid cancer, and three of the five patients had
endometrial cancer, suggesting that these VUSs are asso-
ciated with neoplastic risk. All five patients ultimately
were given diagnoses of at least one component malig-
nancy, and three (60%) were diagnosed with two com-
ponent malignancies.
Through more-detailed functional analysis of the VUSs
located within the PTEN 5′ UTR, we have now elucidated
this mechanism in three of five patients with CS, each of
whom harbors a previously uncharacterized promoter
VUS (specifically, 861G/T, 853C/G, and 764G/C).
However, our data indicate that aberrant protein trans-
lation likely is not the primary mechanism of CS devel-
opment in patients with the 834C/T and 798G/C var-
iants. One can speculate that, within the patients that
have these two VUSs, a specific haplotype may be playing
a key role14 or the PTEN protein function may be altered.41
This suggests that the region upstream of PTEN plays an
important role in the development of CS; however, the
precise pathomechanism(s) of these mutations remains to
be elucidated.
Our data reinforce the importance of PTEN promoter
nucleotide variations and their ability to lead to CS pro-
gression through protein-translation inhibition. As dis-
cussed, patients with CS with promoter mutations have a
high prevalence of breast, thyroid, and endometrial ma-
lignancies, and an understanding of the mechanism of
PTEN dysfunction in these patients may lead to rational
targeted therapies to treat or prevent malignancy. Our data
suggest that a therapeutic tool that can regulate its tran-
scription and/or translation, such as Lovastatin28 or an
eIF4F target, could be highly effective for patients with
germline nucleotide alterations within this region or in
sporadic tumors with somatic 5′-UTR VUSs. Moreover, our
data also reiterate the importance of looking for variants
within the PTEN promoter and even elsewhere in the 5′
UTR of patients who have CS features yet do not have a
detectable mutation within its ORF. This approach should
increase the frequency of finding germline PTEN muta-
tions in PHTS, thus increasing the sensitivity of molecular
diagnosis, and hence broadening those families amenable
to predictive testing. Furthermore, this knowledge can be
extended to other diseases and to their respective suscep-
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tibility genes. Currently, promoters are rarely analyzed in
the clinical setting; therefore, it is very likely that nucle-
otide changes will be identified in many other genes and
that these patients may also benefit from personalized
treatment, given their promoter-mutation status.
Acknowledgments
This work was funded in part by American Cancer Society grant
RSG-02–151–01-CCE (to C.E.). R.E.T. and M.G.P. are predoctoral
fellows of the Cleveland Clinic Genomic Medicine Institute and
are graduate students of the Integrated Biomedical Sciences Grad-
uate Program of The Ohio State University (Columbus). K.M.Z.
is a Crile Fellow of the Cleveland Clinic. C.E. is a recipient of the
Doris Duke Distinguished Clinical Scientist Award. The authors
thank Mr. Todd Romigh (C.E.’s lab) for constructing the vectors,
Dr. X. P. Zhou for technical assistance during the early phases of
this work, and, especially, Drs. Jodi Bubenik, Donna Driscoll, Don
Luse, and Kwaku Dayie for their insight and critical discussions.
R.E.T. also acknowledges Dr. Yufang Tang, Ms. Pat Kessler, Mr.
Robert Pilarski, and Ms. Jennifer Stein for helpful discussions.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
Alibaba, http://www.gene-regulation.com/pub/programs/alibaba2/
index.html
Genomic Medicine Biorepository of the Cleveland Clinic Ge-
nomic Medicine Institute, http://www.lerner.ccf.org/gmi/gmb/
methods.php
MFOLD, http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple
.html
National Comprehensive Cancer Network, http://www.nccn.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for CS, BRRS, and Proteus syndrome)
TESS, http://www.cbil.upenn.edu/cgi-bin/tess/tess
TFSEARCH, http://www.cbrc.jp/research/db/TFSEARCH.html
References
1. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S,
Call KM, Tsou HC, Peacocke M, et al (1997) Germline mu-
tations of the PTEN gene in Cowden disease, an inherited
breast and thyroid cancer syndrome. Nat Genet 16:64–67
2. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed
SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, et al (1999)
PTEN mutation spectrum and genotype-phenotype correla-
tions in Bannayan-Riley-Ruvalcaba syndrome suggest a single
entity with Cowden syndrome. Hum Mol Genet 8:1461–1472
3. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos
C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, et al
(2003) Germline PTEN promoter mutations and deletions in
Cowden/Bannayan-Riley-Ruvalcaba syndrome result in ab-
errant PTEN protein and dysregulation of the phosphoinos-
itol-3-kinase/Akt pathway. Am J Hum Genet 73:404–411
4. Witman PM (2006) More than just a bump: the hamartoma
syndromes. Adv Dermatol 22:157–180
5. Zbuk KM, Eng C (2007) Cancer phenomics: RET and PTEN
as illustrative models. Nat Rev Cancer 7:35–45
6. Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat
22:183–198
7. Ries LAG, Eigne EM, Kosary CL, Hankey BF, Miller BA, Clegg
L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (2003) SEER
cancer statistics review, 1975–2000. National Cancer Insti-
tute, Bethesda, MD
8. Pilarski R, Eng C (2004) Will the real Cowden syndrome
please stand up (again)? Expanding mutational and clinical
spectra of the PTEN hamartoma tumour syndrome. J Med
Genet 41:323–326
9. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA (1992) Ban-
nayan-Riley-Ruvalcaba syndrome. Am J Med Genet 44:307–
314
10. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M,
Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, et
al (2005) Subset of individuals with autism spectrum disor-
ders and extreme macrocephaly associated with germline
PTEN tumour suppressor gene mutations. J Med Genet 42:
318–321
11. Eng C (2000) Will the real Cowden syndrome please stand
up: revised diagnostic criteria. J Med Genet 37:828–830
12. Pezzolesi MG, Zbuk KM, Waite KA, Eng C (2007) Comparative
genomic and functional analyses reveal a novel cis-acting
PTEN regulatory element as a highly conserved functional E-
box motif deleted in Cowden syndrome. Hum Mol Genet 16:
1058–1071
13. Tang Y, Eng C (2006) p53 Down-regulates phosphatase and
tensin homologue deleted on chromosome 10 protein sta-
bility partially through caspase-mediated degradation in cells
with proteasome dysfunction. Cancer Res 66:6139–6148
14. Pezzolesi MG, Li Y, Zhou XP, Pilarski R, Shen L, Eng C (2006)
Mutation-positive and mutation-negative patients with Cow-
den and Bannayan-Riley-Ruvalcaba syndromes associated
with distinct 10q haplotypes. Am J Hum Genet 79:923–934
15. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I,
Zhang JT, Reddy SA, Sabapathy K (2007) c-Jun promotes cel-
lular survival by suppression of PTEN. Cell Death Differ 14:
218–229
16. Laemmli UK (1970) Cleavage of structural proteins during
the assembly of the head of bacteriophage T4. Nature 227:
680–685
17. Sarquis MS, Agrawal S, Shen L, Pilarski R, Zhou XP, Eng C
(2006) Distinct expression profiles for PTEN transcript and
its splice variants in Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome. Am J Hum Genet 79:23–30
18. Sheng X, Koul D, Liu JL, Liu TJ, Yung WK (2002) Promoter
analysis of tumor suppressor gene PTEN: identification of
minimum promoter region. Biochem Biophys Res Commun
292:422–426
19. Han B, Dong Z, Liu Y, Chen Q, Hashimoto K, Zhang JT (2003)
Regulation of constitutive expression of mouse PTEN by the
5′-untranslated region. Oncogene 22:5325–5337
20. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y,
Benchimol S, Mak TW (2001) Regulation of PTEN transcrip-
tion by p53. Mol Cell 8:317–325
21. Vasudevan KM, Gurumurthy S, Rangnekar VM (2004) Sup-
pression of PTEN expression by NF-kappa B prevents apo-
ptosis. Mol Cell Biol 24:1007–1021
22. Zuker M (1989) On finding all suboptimal foldings of an RNA
molecule. Science 244:48–52
23. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA (2004)
Aberrant regulation of survivin by the RB/E2F family of pro-
teins. J Biol Chem 279:40511–40520
24. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin
www.ajhg.org The American Journal of Human Genetics Volume 81 October 2007 767
T, de Belle I (2001) The Egr-1 transcription factor directly
activates PTEN during irradiation-induced signalling. Nat
Cell Biol 3:1124–1128
25. Whelan JT, Forbes SL, Bertrand FE (2007) CBF-1 (RBP-Jkappa)
binds to the PTEN promoter and regulates PTEN gene ex-
pression. Cell Cycle 6:80–84
26. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M,
Middea E, Giordano F, Ando S (2005) Estrogen receptor alpha
binds to peroxisome proliferator-activated receptor response
element and negatively interferes with peroxisome prolifer-
ator-activated receptor gamma signaling in breast cancer
cells. Clin Cancer Res 11:6139–6147
27. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH
(2001) Tumor suppressor and anti-inflammatory actions of
PPARgamma agonists are mediated via upregulation of PTEN.
Curr Biol 11:764–768
28. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng
C (2006) Increased PTEN expression due to transcriptional
activation of PPARgamma by Lovastatin and Rosiglitazone.
Int J Cancer 118:2390–2398
29. Schung J, Overton GC (1997) Technical report CBIL-TR-1997-
1001-v0.0. School of Medicine, University of Pennsylvania,
Philadelphia
30. Grabe N (2002) AliBaba2: context specific identification of
transcription factor binding sites. In Silico Biol 2:S1–S15
31. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE,
Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kol-
pakov FA, et al (1998) Databases on transcriptional regula-
tion: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26:
362–367
32. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF,
Roberts RL, Hayward SW (2005) Unopposed c-MYC expres-
sion in benign prostatic epithelium causes a cancer pheno-
type. Prostate 63:369–384
33. Signori E, Bagni C, Papa S, Primerano B, Rinaldi M, Amaldi
F, Fazio VM (2001) A somatic mutation in the 5′UTR of BRCA1
gene in sporadic breast cancer causes down-modulation of
translation efficiency. Oncogene 20:4596–4600
34. Kozak M (1986) Point mutations define a sequence flanking
the AUG initiator codon that modulates translation by eu-
karyotic ribosomes. Cell 44:283–292
35. Mignone F, Gissi C, Liuni S, Pesole G (2002) Untranslated
regions of mRNAs. Genome Biol 3:REVIEWS0004
36. Saxena A, de Lagarde D, Leonard H, Williamson SL, Vasu-
devan V, Christodoulou J, Thompson E, MacLeod P, Ravine
D (2006) Lost in translation: translational interference from
a recurrent mutation in exon 1 of MECP2. J Med Genet 43:
470–477
37. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM,
Ambudkar SV, Gottesman MM (2007) A “silent” polymor-
phism in the MDR1 gene changes substrate specificity. Sci-
ence 315:525–528
38. Komar AA (2007) Genetics: SNPs, silent but not invisible.
Science 315:466–467
39. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Kor-
chynskyi O, Makarov SS, Maixner W, Diatchenko L (2006)
Human catechol-O-methyltransferase haplotypes modulate
protein expression by altering mRNA secondary structure.
Science 314:1930–1933
40. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G,
Belsham GJ, Sonenberg N (2001) The requirement for eu-
karyotic initiation factor 4A (elF4A) in translation is in direct
proportion to the degree of mRNA 5′ secondary structure.
RNA 7:382–394
41. Chung JH, Eng C (2005) Nuclear-cytoplasmic partitioning of
phosphatase and tensin homologue deleted on chromosome
10 (PTEN) differentially regulates the cell cycle and apoptosis.
Cancer Res 65:8096–8100
